272 related articles for article (PubMed ID: 33764249)
1. Kinetics of radium-223 and its effects on survival, proliferation and DNA damage in lymph-node and bone metastatic prostate cancer cell lines.
Marques IA; Abrantes AM; Pires AS; Neves AR; Caramelo FJ; Rodrigues T; Matafome P; Tavares-da-Silva E; Gonçalves AC; Pereira CC; Teixeira JP; Seiça R; Costa G; Figueiredo A; Botelho MF
Int J Radiat Biol; 2021; 97(5):714-726. PubMed ID: 33764249
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
Isaacsson Velho P; Qazi F; Hassan S; Carducci MA; Denmeade SR; Markowski MC; Thorek DL; DeWeese TL; Song DY; Tran PT; Eisenberger MA; Antonarakis ES
Eur Urol; 2019 Aug; 76(2):170-176. PubMed ID: 30293905
[TBL] [Abstract][Full Text] [Related]
3. Radium-223 for the treatment of metastatic castration-resistant prostate cancer: A window of opportunity.
Gómez-Veiga F; Álvarez-Ossorio JL; Carballido-Rodríguez J; Juárez-Soto A; Rodríguez-Antolín A; Cozar-Olmo JM
Actas Urol Esp (Engl Ed); 2018 Dec; 42(10):616-624. PubMed ID: 30041891
[TBL] [Abstract][Full Text] [Related]
4. [Radium-223 for the treatment of metastatic castration-resistant prostate cancer (mCRPC) : The androgen receptor-independent active agent in the therapeutic sequence].
König F; Strauß A; Johannsen M; Mommsen C; Fricke E; Klier J; Mehl S; Pfister D; Sahlmann CO; Werner A; Goebell PJ
Urologe A; 2020 Jan; 59(1):53-64. PubMed ID: 31598745
[TBL] [Abstract][Full Text] [Related]
5. Radium-223 in Metastatic Castration-Resistant Prostate Cancer: Clinical Development and Use in Contemporary Practice.
Morgan SC
J Med Imaging Radiat Sci; 2019 Dec; 50(4S1):S26-S30. PubMed ID: 31231006
[TBL] [Abstract][Full Text] [Related]
6. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.
Armstrong AJ; Gupta S; Healy P; Kemeny G; Leith B; Zalutsky MR; Spritzer C; Davies C; Rothwell C; Ware K; Somarelli JA; Wood K; Ribar T; Giannakakou P; Zhang J; Gerber D; Anand M; Foo WC; Halabi S; Gregory SG; George DJ
PLoS One; 2019; 14(5):e0216934. PubMed ID: 31136607
[TBL] [Abstract][Full Text] [Related]
8. Optimal usage of radium-223 in metastatic castration-resistant prostate cancer.
Cha TL; Wu TT; Vogelzang NJ; Huang CY; Huang SP; Lin CC; Ou YC; Pang ST; Shen DH; Wu WJ; Chang WY
J Formos Med Assoc; 2017 Nov; 116(11):825-836. PubMed ID: 29046247
[TBL] [Abstract][Full Text] [Related]
9. Radium 223 dichloride for prostate cancer treatment.
Deshayes E; Roumiguie M; Thibault C; Beuzeboc P; Cachin F; Hennequin C; Huglo D; Rozet F; Kassab-Chahmi D; Rebillard X; Houédé N
Drug Des Devel Ther; 2017; 11():2643-2651. PubMed ID: 28919714
[TBL] [Abstract][Full Text] [Related]
10. Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review.
Cursano MC; Iuliani M; Casadei C; Stellato M; Tonini G; Paganelli G; Santini D; De Giorgi U
Crit Rev Oncol Hematol; 2020 Feb; 146():102864. PubMed ID: 31986318
[TBL] [Abstract][Full Text] [Related]
11. Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?
Serretta V; Valerio MR; Costa R; Tripoli V; Murabito A; Princiotta A; Scalici Gesolfo C; Borsellino N; Verderame F; Gebbia V; Licari M; Sanfilippo C;
Urol Oncol; 2019 Dec; 37(12):964-969. PubMed ID: 31601517
[TBL] [Abstract][Full Text] [Related]
12. Dynamic changes of bone metastasis predict bone-predominant status to benefit from radium-223 dichloride for patients with castration-resistant prostate cancer.
Hashimoto K; Miyoshi Y; Shindo T; Hori M; Tsuboi Y; Kobayashi K; Fukuta F; Tanaka T; Miyamoto S; Maehana T; Okada M; Nishiyama N; Yanase M; Kato R; Hotta H; Kunishima Y; Takahashi A; Hinotsu S; Sakata KI; Kitamura H; Uemura H; Masumori N
Cancer Med; 2020 Nov; 9(22):8579-8588. PubMed ID: 32964674
[TBL] [Abstract][Full Text] [Related]
13. Radium-223 dichloride: a new paradigm in the treatment of prostate cancer.
Anido Herranz U; Fernández Calvo O; Afonso Afonso FJ; Rodríguez Martínez de Llano S; Lázaro Quintela M; León Mateos L; Vázquez Estévez S; Antón Aparicio LM
Expert Rev Anticancer Ther; 2015 Mar; 15(3):339-48. PubMed ID: 25555355
[TBL] [Abstract][Full Text] [Related]
14. Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.
Picciotto M; Franchina T; Russo A; Ricciardi GRR; Provazza G; Sava S; Baldari S; Caffo O; Adamo V
Expert Opin Pharmacother; 2017 Jun; 18(9):899-908. PubMed ID: 28449621
[TBL] [Abstract][Full Text] [Related]
15. Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel.
Baldari S; Boni G; Bortolus R; Caffo O; Conti G; De Vincentis G; Monari F; Procopio G; Santini D; Seregni E; Valdagni R
Crit Rev Oncol Hematol; 2017 May; 113():43-51. PubMed ID: 28427521
[TBL] [Abstract][Full Text] [Related]
16. Radium 223 for the treatment of metastatic castration-resistant prostate cancer.
Miranda J; Viñal D; Pinto Á
Arch Esp Urol; 2019 Jun; 72(5):500-507. PubMed ID: 31223127
[TBL] [Abstract][Full Text] [Related]
17. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
[TBL] [Abstract][Full Text] [Related]
18. Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer.
Borsò E; Boni G; Galli L; Ricci S; Farnesi A; Mazzarri S; Cianci C; Mariani G; Falcone A
Future Oncol; 2015; 11(2):323-31. PubMed ID: 25075962
[TBL] [Abstract][Full Text] [Related]
19. [Radium-223 dichloride in patients with castration-refractory prostate cancer].
Winter BM; von Rundstedt FC; Grimm MO
Urologe A; 2017 Nov; 56(11):1435-1439. PubMed ID: 29022046
[TBL] [Abstract][Full Text] [Related]
20. Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial.
Morris MJ; Loriot Y; Sweeney CJ; Fizazi K; Ryan CJ; Shevrin DH; Antonarakis ES; Pandit-Taskar N; Deandreis D; Jacene HA; Vesselle H; Petrenciuc O; Lu C; Carrasquillo JA; Higano CS
Eur J Cancer; 2019 Jun; 114():107-116. PubMed ID: 31082669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
